Fate Therapeutics (FATE) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Fate Therapeutics (FATE) Tops Q4 EPS by 1c

Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study

March 4, 2016 9:49 AM EST

Leerink Partners maintained an Outperform rating on Fate Therapeutics (NASDAQ: FATE), and cut the price target to $4.00 (from $8.00), following the company's 4Q earnings report. FATE's reported EPS of ($0.26) was slightly better than estimate' of ($0.28). The company also announced that it anticipates initiating the Phase I/II study of ProTmune in... More